Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 635

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

Open access
Melander, Hans, Ahlqvist-Rastad, Jane, Meijer, Gertie, Beermann, Björn·2003·BMJ
DOI 10.1136/bmj.326.7400.1171
Open this paper in CoChat — free account

Abstract

Objectives To investigate the relative impact on publication bias caused by multiple publication, selective publication, and selective reporting in studies sponsored by pharmaceutical companies. Design 42 placebo controlled studies of five selective serotonin reuptake inhibitors submitted to the Swedish drug regulatory authority as a basis for marketing approval for treating major depression were compared with the studies actually published (between 1983 and 1999). Results Multiple publication: 21 studies contributed to at least two publications each, and three studies contributed to five publications. Selective publication: studies showing significant effects of drug were published as stand alone publications more often than studies with non-significant results. Selective reporting: many publications ignored the results of intention to treat analyses and reported the more favourable per protocol analyses only. Conclusions The degree of multiple publication, selective publication, and selective reporting differed between products. Thus, any attempt to recommend a specific selective serotonin reuptake inhibitor from the publicly available data only is likely to be based on biased evidence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.326.7400.1171

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 41

  1. 10.1001/jama.1990.03440100121018 · DOI · Paper page
  2. 10.1016/S0140-6736(01)06035-4 · DOI
  3. Dickersin, 1992, Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards., JAMA, 263, 374, 10.1001/jama.1992.03480030052036 · DOI · Paper page
  4. Amin, 1984, Fluvoxamine: antidepressant effects confirmed in a placebo-controlled international study., Clin Neuropharmacol, 7, 580
  5. Bech, 1992, Citalopram in depression—meta-analysis of intended and unintended effects., Int Clin Psychopharmacol, 6, 45, 10.1097/00004850-199206005-00005 · DOI
  6. Byerley, 1988, Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression., J Clin Psychopharmacol, 8, 112, 10.1097/00004714-198804000-00005 · DOI · Paper page
  7. Claghorn, 1992, Paroxetine versus placebo: a double-blind comparison in depressed patients., J Clin Psychiatry, 53, 434
  8. Claghorn, 1992, A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients., Int Clin Psychopharmacol, 6, 25, 10.1097/00004850-199206004-00006 · DOI
  9. Claghorn, 1992, The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients., J Clin Psychiatry, 53, 33
  10. Cohn, 1985, A comparison of fluoxetine, imipramine, and placebo inpatients with major depressive disorder., J Clin Psychiatry, 46, 26
  11. Cohn, 1992, Paroxetine in major depression: a double-blind trial with imipramine and placebo., J Clin Psychiatry, 53, 52
  12. Dominguez, 1985, A double-blind placebo-controlled study of fluvoxamine and imipramine in depression., J Clin Psychiatry, 46, 84
  13. Doogan, 1994, A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice., Int Clin Psychopharmacol, 9, 95, 10.1097/00004850-199400920-00005 · DOI
  14. Dunbar, 1993, A comparison of paroxetine and placebo in depressed outpatients., Acta Psychiatr Scand, 87, 302, 10.1111/j.1600-0447.1993.tb03376.x · DOI · Paper page
  15. 10.1192/bjp.159.3.394 · DOI
  16. 10.1002/hup.470080306 · DOI
  17. Fabre, 1992, A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients., J Clin Psychiatry, 53, 40
  18. Feighner, 1989, A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression., Int Clin Psychopharmacol, 4, 127, 10.1097/00004850-198904000-00004 · DOI
  19. Feighner, 1989, A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression., Int Clin Psychopharmacol, 4, 239, 10.1097/00004850-198907000-00006 · DOI
  20. Feighner, 1993, Paroxetine in the treatment of depression: a comparison with imipramine and placebo., Acta Psychiatr Scand, 80, 125
  21. Feighner, 1992, Paroxetine in the treatment of depression: a comparison with imipramine and placebo., J Clin Psychiatry, 53, 44
  22. Feighner, 1993, A study comparing paroxetine, placebo and imipramine in depressed patients., J Affect Dis, 28, 71, 10.1016/0165-0327(93)90035-I · DOI
  23. 10.1016/0165-0327(93)90035-I · DOI
  24. Itil, 1983, A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression., Br J Clin Pharmacol, 15, 433, 10.1111/j.1365-2125.1983.tb02134.x · DOI
  25. Kiev, 1992, A double-blind, placebo-controlled study of paroxetine in depressed outpatients., J Clin Psychiatry, 53, 27
  26. LaPierre, 1987, Treatment of major affective disorder with fluvoxamine., J Clin Psychiatry, 48, 65
  27. Mendels, 1999, Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia., Depress Anxiety, 9, 54, 10.1002/(SICI)1520-6394(1999)9:2<54::AID-DA2>3.0.CO;2-T · DOI
  28. 10.1002/(SICI)1520-6394(1999)9:2<54::AID-DA2>3.0.CO;2-T · DOI
  29. Montgomery, 1992, Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression., Int Clin Psychopharmacol, 6, 65, 10.1097/00004850-199206005-00007 · DOI
  30. Norton, 1984, A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients., J Affect Dis, 7, 297, 10.1016/0165-0327(84)90051-X · DOI
  31. 10.1016/0165-0327(84)90051-X · DOI
  32. Ottevanger, 1994, The efficacy of fluvoxamine in patients with severe depression., Prog Neuropsychopharmacol Biol Psychiatry, 18, 731, 10.1016/0278-5846(94)90080-9 · DOI
  33. 10.1016/0278-5846(94)90080-9 · DOI
  34. Reimherr, 1990, Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline controlled, multicenter comparison study in outpatients with major depression., J Clin Psychiatry, 51, 18
  35. Rickels, 1993, A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients., Acta Psychiatr Scand, 80, 117
  36. Rickels, 1992, The efficacy and safety of paroxetine compared with placebo in outpatients with major depression., J Clin Psychiatry, 53, 30
  37. Rickels, 1986, Fluoxetine in major depression: a controlled study., Curr Ther Res, 39, 559
  38. Shrivastava, 1992, A double-blind comparison of paroxetine, imipramine, and placebo in major depression., J Clin Psychiatry, 53, 48
  39. Smith, 1992, A placebo-controlled trial of paroxetine in the treatment of major depression., J Clin Psychiatry, 53, 36
  40. Stark, 1985, A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder., J Clin Psychiatry, 46, 53
  41. Dickersin, 1997, How important is publication bias? A synthesis of available data., AIDS Educ Prev, 9, 15

Cited by

See all 635

Metadata

Authors
Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B.
Venue
BMJ
Publisher
BMJ
Published
2003-05-29
Volume
326
Issue
7400
Pages
1171-1173
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
DOI
10.1136/bmj.326.7400.1171
OpenAlex
W2105662053
Cited by
635
References
8
FWCI
33.52
Type
journal article
Language
en
Open access
hybrid
Licence
www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.